Matt Miksic
Stock Analyst at Barclays
(3.84)
# 623
Out of 4,883 analysts
282
Total ratings
61.33%
Success rate
4.37%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $19 → $16 | $13.88 | +15.27% | 5 | Jun 9, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $261 → $241 | $176.16 | +36.81% | 1 | Jun 3, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $56 → $55 | $46.13 | +19.23% | 7 | May 8, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $16 → $12 | $2.89 | +315.22% | 2 | May 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $90 → $93 | $82.93 | +12.14% | 6 | May 5, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $301.05 | -11.64% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $15.16 | +58.31% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $104.32 | +19.82% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $544.47 | +16.63% | 7 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $165 | $156.01 | +5.76% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $134.44 | +18.27% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $31.01 | +32.22% | 21 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $53 | $16.78 | +215.85% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $59.17 | +74.07% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $76.79 | +17.20% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $93.67 | +19.57% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $395.28 | +12.07% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $10.99 | +91.08% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.80 | +478.95% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $88.39 | +23.32% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $10.25 | +56.10% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $87.78 | +9.36% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $74.67 | +33.92% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $196.82 | +112.38% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $11.75 | +138.40% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $16.67 | +301.92% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $7.61 | +6,207.49% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $13.49 | +544.92% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.25 | +488.24% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.34 | +41.96% | 1 | Dec 12, 2016 |
Bausch + Lomb
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $13.88
Upside: +15.27%
Becton, Dickinson and Company
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $176.16
Upside: +36.81%
LivaNova
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $46.13
Upside: +19.23%
Orchestra BioMed Holdings
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.89
Upside: +315.22%
DexCom
May 5, 2025
Maintains: Equal-Weight
Price Target: $90 → $93
Current: $82.93
Upside: +12.14%
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $301.05
Upside: -11.64%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $15.16
Upside: +58.31%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $104.32
Upside: +19.82%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $544.47
Upside: +16.63%
Johnson & Johnson
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $166 → $165
Current: $156.01
Upside: +5.76%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $134.44
Upside: +18.27%
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $31.01
Upside: +32.22%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $16.78
Upside: +215.85%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $59.17
Upside: +74.07%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $76.79
Upside: +17.20%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $93.67
Upside: +19.57%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $395.28
Upside: +12.07%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.99
Upside: +91.08%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.80
Upside: +478.95%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $88.39
Upside: +23.32%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $10.25
Upside: +56.10%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $87.78
Upside: +9.36%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $74.67
Upside: +33.92%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $196.82
Upside: +112.38%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.75
Upside: +138.40%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $16.67
Upside: +301.92%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $7.61
Upside: +6,207.49%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $13.49
Upside: +544.92%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.25
Upside: +488.24%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.34
Upside: +41.96%